In vitro metabolism of oprozomib, an oral proteasome inhibitor: Role of epoxide hydrolases and cytochrome P450ss

Zhican Wang, Ying Fang, Juli Teague, Hansen Wong, Christophe Morisseau, Bruce D. Hammock, Dan A. Rock, Zhengping Wang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Oprozomib is an oral proteasome inhibitor currently under investigation in patients with hematologic malignancies or solid tumors. Oprozomib elicits potent pharmacological actions by forming a covalent bond with the active site N-terminal threonine of the 20S proteasome. Oprozomib has a short half-life across preclinical species and in patients due to systemic clearance via metabolism. Potential for drug-drug interactions (DDIs) could alter the exposure of this potent therapeutic; therefore, a thorough investigation of pathways responsible for metabolism is required. In the present study, the major drug-metabolizing enzyme responsible for oprozomib metabolism was identified in vitro. A diol of oprozomib was found to be the predominant metabolite in human hepatocytes, which formed via direct epoxide hydrolysis. Using recombinant epoxide hydrolases (EHs) and selective EH inhibitors in liver microsomes, microsomal EH (mEH) but not soluble EH (sEH) was found to be responsible for oprozomib diol formation. Coincubation with 2-nonylsulfanyl-propionamide, a selective mEH inhibitor, resulted in a significant decrease in oprozomib disappearance (>80%) with concurrent complete blockage of diol formation in human hepatocytes. On the contrary, a selective sEH inhibitor did not affect oprozomib metabolism. Pretreatment of hepatocytes with the pan-cytochrome P450 (P450) inhibitor 1-aminobenzotriazole resulted in a modest reduction (~20%) of oprozomib metabolism. These findings indicated that mEH plays a predominant role in oprozomib metabolism. Further studies may be warranted to determine whether drugs that are mEH inhibitors cause clinically significant DDIs with oprozomib. On the other hand, pharmacokinetics of oprozomib is unlikely to be affected by coadministered P450 and sEH inhibitors and/or inducers.

Original languageEnglish (US)
Pages (from-to)712-720
Number of pages9
JournalDrug Metabolism and Disposition
Volume45
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Epoxide Hydrolases
Proteasome Inhibitors
Cytochromes
Hepatocytes
Drug Interactions
Pharmaceutical Preparations
In Vitro Techniques
ONX 0912
Epoxy Compounds
Liver Microsomes
Hematologic Neoplasms
Proteasome Endopeptidase Complex
Threonine
Cytochrome P-450 Enzyme System
Half-Life
Catalytic Domain
Hydrolysis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

In vitro metabolism of oprozomib, an oral proteasome inhibitor : Role of epoxide hydrolases and cytochrome P450ss. / Wang, Zhican; Fang, Ying; Teague, Juli; Wong, Hansen; Morisseau, Christophe; Hammock, Bruce D.; Rock, Dan A.; Wang, Zhengping.

In: Drug Metabolism and Disposition, Vol. 45, No. 7, 01.07.2017, p. 712-720.

Research output: Contribution to journalArticle

Wang, Z, Fang, Y, Teague, J, Wong, H, Morisseau, C, Hammock, BD, Rock, DA & Wang, Z 2017, 'In vitro metabolism of oprozomib, an oral proteasome inhibitor: Role of epoxide hydrolases and cytochrome P450ss', Drug Metabolism and Disposition, vol. 45, no. 7, pp. 712-720. https://doi.org/10.1124/dmd.117.075226
Wang, Zhican ; Fang, Ying ; Teague, Juli ; Wong, Hansen ; Morisseau, Christophe ; Hammock, Bruce D. ; Rock, Dan A. ; Wang, Zhengping. / In vitro metabolism of oprozomib, an oral proteasome inhibitor : Role of epoxide hydrolases and cytochrome P450ss. In: Drug Metabolism and Disposition. 2017 ; Vol. 45, No. 7. pp. 712-720.
@article{4dd0f0789383483497a45c0e7f3c3e02,
title = "In vitro metabolism of oprozomib, an oral proteasome inhibitor: Role of epoxide hydrolases and cytochrome P450ss",
abstract = "Oprozomib is an oral proteasome inhibitor currently under investigation in patients with hematologic malignancies or solid tumors. Oprozomib elicits potent pharmacological actions by forming a covalent bond with the active site N-terminal threonine of the 20S proteasome. Oprozomib has a short half-life across preclinical species and in patients due to systemic clearance via metabolism. Potential for drug-drug interactions (DDIs) could alter the exposure of this potent therapeutic; therefore, a thorough investigation of pathways responsible for metabolism is required. In the present study, the major drug-metabolizing enzyme responsible for oprozomib metabolism was identified in vitro. A diol of oprozomib was found to be the predominant metabolite in human hepatocytes, which formed via direct epoxide hydrolysis. Using recombinant epoxide hydrolases (EHs) and selective EH inhibitors in liver microsomes, microsomal EH (mEH) but not soluble EH (sEH) was found to be responsible for oprozomib diol formation. Coincubation with 2-nonylsulfanyl-propionamide, a selective mEH inhibitor, resulted in a significant decrease in oprozomib disappearance (>80{\%}) with concurrent complete blockage of diol formation in human hepatocytes. On the contrary, a selective sEH inhibitor did not affect oprozomib metabolism. Pretreatment of hepatocytes with the pan-cytochrome P450 (P450) inhibitor 1-aminobenzotriazole resulted in a modest reduction (~20{\%}) of oprozomib metabolism. These findings indicated that mEH plays a predominant role in oprozomib metabolism. Further studies may be warranted to determine whether drugs that are mEH inhibitors cause clinically significant DDIs with oprozomib. On the other hand, pharmacokinetics of oprozomib is unlikely to be affected by coadministered P450 and sEH inhibitors and/or inducers.",
author = "Zhican Wang and Ying Fang and Juli Teague and Hansen Wong and Christophe Morisseau and Hammock, {Bruce D.} and Rock, {Dan A.} and Zhengping Wang",
year = "2017",
month = "7",
day = "1",
doi = "10.1124/dmd.117.075226",
language = "English (US)",
volume = "45",
pages = "712--720",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "7",

}

TY - JOUR

T1 - In vitro metabolism of oprozomib, an oral proteasome inhibitor

T2 - Role of epoxide hydrolases and cytochrome P450ss

AU - Wang, Zhican

AU - Fang, Ying

AU - Teague, Juli

AU - Wong, Hansen

AU - Morisseau, Christophe

AU - Hammock, Bruce D.

AU - Rock, Dan A.

AU - Wang, Zhengping

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Oprozomib is an oral proteasome inhibitor currently under investigation in patients with hematologic malignancies or solid tumors. Oprozomib elicits potent pharmacological actions by forming a covalent bond with the active site N-terminal threonine of the 20S proteasome. Oprozomib has a short half-life across preclinical species and in patients due to systemic clearance via metabolism. Potential for drug-drug interactions (DDIs) could alter the exposure of this potent therapeutic; therefore, a thorough investigation of pathways responsible for metabolism is required. In the present study, the major drug-metabolizing enzyme responsible for oprozomib metabolism was identified in vitro. A diol of oprozomib was found to be the predominant metabolite in human hepatocytes, which formed via direct epoxide hydrolysis. Using recombinant epoxide hydrolases (EHs) and selective EH inhibitors in liver microsomes, microsomal EH (mEH) but not soluble EH (sEH) was found to be responsible for oprozomib diol formation. Coincubation with 2-nonylsulfanyl-propionamide, a selective mEH inhibitor, resulted in a significant decrease in oprozomib disappearance (>80%) with concurrent complete blockage of diol formation in human hepatocytes. On the contrary, a selective sEH inhibitor did not affect oprozomib metabolism. Pretreatment of hepatocytes with the pan-cytochrome P450 (P450) inhibitor 1-aminobenzotriazole resulted in a modest reduction (~20%) of oprozomib metabolism. These findings indicated that mEH plays a predominant role in oprozomib metabolism. Further studies may be warranted to determine whether drugs that are mEH inhibitors cause clinically significant DDIs with oprozomib. On the other hand, pharmacokinetics of oprozomib is unlikely to be affected by coadministered P450 and sEH inhibitors and/or inducers.

AB - Oprozomib is an oral proteasome inhibitor currently under investigation in patients with hematologic malignancies or solid tumors. Oprozomib elicits potent pharmacological actions by forming a covalent bond with the active site N-terminal threonine of the 20S proteasome. Oprozomib has a short half-life across preclinical species and in patients due to systemic clearance via metabolism. Potential for drug-drug interactions (DDIs) could alter the exposure of this potent therapeutic; therefore, a thorough investigation of pathways responsible for metabolism is required. In the present study, the major drug-metabolizing enzyme responsible for oprozomib metabolism was identified in vitro. A diol of oprozomib was found to be the predominant metabolite in human hepatocytes, which formed via direct epoxide hydrolysis. Using recombinant epoxide hydrolases (EHs) and selective EH inhibitors in liver microsomes, microsomal EH (mEH) but not soluble EH (sEH) was found to be responsible for oprozomib diol formation. Coincubation with 2-nonylsulfanyl-propionamide, a selective mEH inhibitor, resulted in a significant decrease in oprozomib disappearance (>80%) with concurrent complete blockage of diol formation in human hepatocytes. On the contrary, a selective sEH inhibitor did not affect oprozomib metabolism. Pretreatment of hepatocytes with the pan-cytochrome P450 (P450) inhibitor 1-aminobenzotriazole resulted in a modest reduction (~20%) of oprozomib metabolism. These findings indicated that mEH plays a predominant role in oprozomib metabolism. Further studies may be warranted to determine whether drugs that are mEH inhibitors cause clinically significant DDIs with oprozomib. On the other hand, pharmacokinetics of oprozomib is unlikely to be affected by coadministered P450 and sEH inhibitors and/or inducers.

UR - http://www.scopus.com/inward/record.url?scp=85021074834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021074834&partnerID=8YFLogxK

U2 - 10.1124/dmd.117.075226

DO - 10.1124/dmd.117.075226

M3 - Article

AN - SCOPUS:85021074834

VL - 45

SP - 712

EP - 720

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 7

ER -